Moberg Pharma AB (publ) financials
Moberg Pharma AB (publ)
549300XFXK7DVGDRP410 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Cost of sales | SEK 3.5M | SEK 0 |
| Gross profit | SEK 6.3M | SEK 0 |
| Other income | SEK 57.0K | SEK 1.1M |
| Operating profit (EBIT) | -SEK 324.8M | -SEK 27.5M |
| Finance costs | SEK 228.0K | SEK 260.0K |
| Profit before tax | -SEK 320.5M | -SEK 25.4M |
| Income tax expense | -SEK 65.4M | -SEK 4.3M |
| Profit for the year | -SEK 255.1M | -SEK 21.1M |
| — attributable to owners | -SEK 255.1M | -SEK 21.1M |
| — attributable to NCI | SEK 0 | SEK 0 |
| Total comprehensive income | -SEK 255.1M | -SEK 21.1M |
| Per share | ||
| Basic EPS | SEK -6.74 | SEK -1.33 |
| Diluted EPS | SEK -6.74 | SEK -1.33 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 16.5M | -SEK 33.2M |
| Net cash from investing activities | -SEK 73.6M | -SEK 124.1M |
| Purchase of intangibles | SEK 73.6M | SEK 124.1M |
| Net cash from financing activities | SEK 322.8M | SEK 92.3M |
| Lease liability payments | SEK 1.4M | SEK 2.4M |
| Net change in cash | SEK 232.7M | -SEK 65.0M |
| Balance sheet | ||
| Total assets | SEK 706.1M | SEK 634.7M |
| Non-current assets | SEK 406.0M | SEK 565.2M |
| Right-of-use assets | SEK 4.4M | SEK 4.9M |
| Current assets | SEK 300.1M | SEK 69.5M |
| Inventories | SEK 4.3M | SEK 7.1M |
| Trade & other receivables | SEK 166.0K | SEK 0 |
| Cash & equivalents | SEK 293.3M | SEK 60.6M |
| Total equity | SEK 686.8M | SEK 610.7M |
| — attributable to owners | SEK 686.8M | SEK 610.7M |
| Non-current liabilities | SEK 2.5M | SEK 3.5M |
| Lease liabilities (non-current) | SEK 2.5M | SEK 3.5M |
| Current liabilities | SEK 16.7M | SEK 20.5M |
| Lease liabilities (current) | SEK 1.6M | SEK 1.3M |
| Derived metrics | ||
| Operating margin | -3310.9% | — |
| Net margin | -2600.3% | — |
| Return on equity | -37.1% | -3.5% |
| Cash conversion ratio | 0.06× | 1.57× |
| Other reported items | ||
| Accruals Classified As Current | SEK 9.0M | SEK 9.2M |
| Additional Paidin Capital | SEK 1.23B | SEK 921.3M |
| Adjusted Weighted Average Shares | 38.9M | 35.5M |
| Adjustments For Decrease Increase In Inventories | SEK 2.8M | -SEK 7.1M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 707.0K | SEK 424.0K |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | SEK 301.3M | SEK 2.1M |
| Adjustments For Increase Decrease In Trade and Other Payables | -SEK 4.1M | -SEK 5.5M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | SEK 0 | SEK 0 |
| Adjustments For Sharebased Payments | SEK 4.7M | SEK 2.3M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 14.4M | -SEK 21.1M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | SEK 0 | SEK 0 |
| Current Prepayments | SEK 1.7M | SEK 1.0M |
| Deferred Tax Assets | SEK 95.8M | SEK 28.1M |
| Equity and Liabilities | SEK 706.1M | SEK 634.7M |
| Finance Income | SEK 4.6M | SEK 2.3M |
| General and Administrative Expense | SEK 21.8M | SEK 21.6M |
| Income Taxes Paid Refund Classified As Operating Activities | SEK 0 | SEK 0 |
| Intangible Assets Other Than Goodwill | SEK 305.8M | SEK 532.2M |
| Intangible Assets Under Development | SEK 305.8M | SEK 532.2M |
| Interest Paid Classified As Operating Activities | -SEK 228.0K | -SEK 260.0K |
| Interest Received Classified As Operating Activities | SEK 4.6M | SEK 2.3M |
| Issue of Equity | SEK 335.5M | SEK 100.6M |
| Issued Capital | SEK 46.7M | SEK 28.0M |
| Liabilities | SEK 19.3M | SEK 24.0M |
| Number of Shares Outstanding | 46.7M | 28.0M |
| Office Equipment | SEK 0 | SEK 0 |
| Other Current Liabilities | SEK 2.0M | SEK 3.3M |
| Other Current Receivables | SEK 638.0K | SEK 786.0K |
| Other Noncurrent Assets | SEK 100.2M | SEK 33.0M |
| Other Noncurrent Liabilities | SEK 0 | SEK 0 |
| Proceeds From Issuing Shares | SEK 324.1M | SEK 94.8M |
| Purchase of Treasury Shares | SEK 0 | SEK 187.0K |
| Research and Development Expense | SEK 302.2M | SEK 3.7M |
| Retained Earnings | -SEK 593.6M | -SEK 338.5M |
| Revenue From Contracts With Customers | SEK 9.8M | SEK 0 |
| Selling Expense | SEK 7.1M | SEK 3.3M |
| Share Issue Related Cost | SEK 11.4M | SEK 5.7M |
| Trade and Other Payables To Trade Suppliers | SEK 4.2M | SEK 6.8M |
| Weighted Average Shares | 37.8M | 15.9M |
Every line item above is a fact tagged in Moberg Pharma AB (publ)'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.